$ACHV
Achieve Life Sciences, Inc.
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
$6.49
▼-0.15%-$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAchieve Life Sciences, Inc.
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
Why is ACHV down today? It is at $6.49 (-0.15%), and our scanner flagged it 84 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ACHV spikes, and full due diligence on ACHV — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ACHV 84 times in the last 30 days. Create a free account to track $ACHV, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ACHV from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ACHV today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystExecutive / Board Change, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Oct 6, 2026 · 18 days agoAcross every filing on file, supply equal to 306.3% of the tradeable float is in play - 306.3% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
20,689,655 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $150.0M in size · Priced at $7.25/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Stewart Richard Alistair Director | Sold (automatic/other) | -21K 0.02% of company | sold 9.0% | 208K | $175K at $8.49 | Aug 19, 26 |
Stewart Richard Alistair Officer | Sold (automatic/other) | -130K 0.1% of company | sold 36% | 229K | $378K at $2.92 | Sep 18, 25 |
Stewart Richard Alistair Officer | Other | 298K 0.3% of company | added 100% | 358K | n/a | Sep 18, 25 |
Oki Mark K Officer | Sold (automatic/other) | -50K 0.05% of company | sold 28% | 128K | $146K at $2.92 | Sep 18, 25 |
Oki Mark K Officer | Other | 168K 0.2% of company | added 100% | 178K | n/a | Sep 18, 25 |
Xinos Jaime Officer | Sold (automatic/other) | -21K 0.02% of company | sold 22% | 74K | $58K at $2.77 | Sep 4, 25 |
Xinos Jaime Officer | Other | 69K 0.07% of company | added 100% | 95K | n/a | Sep 4, 25 |
Jacobs Cindy Officer | Sold (automatic/other) | -28K 0.03% of company | sold 19% | 116K | $77K at $2.77 | Sep 4, 25 |
Jacobs Cindy Officer | Other | 110K 0.1% of company | added 100% | 143K | n/a | Sep 4, 25 |
King Thomas Braxton Director | Sold (automatic/other) | -140K 0.1% of company | sold 31% | 315K | $387K at $2.77 | Sep 4, 25 |
King Thomas Braxton Director | Other | 455K 0.4% of company | n/a | 455K | n/a | Sep 4, 25 |
Wan Jerry Officer | Sold (automatic/other) | -14K 0.01% of company | sold 30% | 33K | $39K at $2.77 | Sep 4, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in in vitro & in vivo diagnostic substances, closest in size first.
Here is the latest on ACHV from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ACHV today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
ACHV last traded at $6.49, down 0.15% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Achieve Life Sciences, Inc. (ACHV) is next expected to report earnings on Thursday, November 5, 2026, about 11 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ACHV Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ACHV 84 times in the last 30 days.
ACHV (Achieve Life Sciences, Inc.) trades on XNAS, with a market cap of about $668M in the In Vitro & In Vivo Diagnostic Substances sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ACHV for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ACHV discussion
Sign in to ask a question or join the discussion.